Market Overview:

Antimicrobial susceptibility testing determines the sensitivity of bacteria, viruses and other microbes to antibiotics used in treatment. It helps clinicians choose the most effective antibiotics for patients with suspected or confirmed bacterial or fungal infections.

Key Takeaways

The Global Antimicrobial Susceptibility Testing Market Size was valued at US$ 3751.4 Mn in 2023 and is expected to reach over US$ 6000 Mn by 2030, expanding at a CAGR of 6.4% during the forecast period.

North America dominated the market in 2023 with over 35% market share. This is owing to rising healthcare investments, developed healthcare infrastructure and presence of leading AST product manufacturers in the region. Asia Pacific exhibits highest growth and is estimated to expand at 7% CAGR between 2023 - 2030 due to growing patient pool, increasing antibiotic resistance and improving access to healthcare in developing countries like India and China.

Key players operating in the antimicrobial susceptibility testing market are Thermo Fisher Scientific Inc., BIOMÉRIEUX, HiMedia Laboratories, Alifax S.r.l. Italy, Creative Diagnostics, Resistell AG, Danaher, Becton, Dickinson and Company, Merck KGaA, Bio-Rad Laboratories, Inc., Bruker, Nissui Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd.,Synbiosis, Mast Group Ltd., ELITechGroup, Flinn Scientific, CONDALAB, Accelerate Diagnostics, Inc. and Zhuhai DL Biotech Co., Ltd. These players are focused on strengthening their product portfolio and expanding to emerging markets through partnerships and acquisitions.

Read More - https://thewion.com/leveraging-digital-technologies-to-accelerate-antimicrobial-susceptibility-testing/